Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple CohortsGlobeNewsWire • 09/03/24
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/29/24
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/12/24
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's WhyZacks Investment Research • 07/29/24
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 07/18/24
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 07/12/24
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseGlobeNewsWire • 06/24/24
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressGlobeNewsWire • 06/13/24
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 05/28/24
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockGlobeNewsWire • 05/22/24
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted AgainInvestors Business Daily • 05/20/24
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsGlobeNewsWire • 05/20/24
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETGlobeNewsWire • 05/19/24
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/02/24
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerGlobeNewsWire • 03/27/24
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumGlobeNewsWire • 03/27/24
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/05/24
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewsWire • 02/14/24